Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company, announced new data from a post hoc analysis of the Phase 2 eNRGy trial (NCT02912949) evaluating zenocutuzumab in ...

Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the first ...

Christy Houvouras, of Huntington, was shocked when she was diagnosed with lung cancer at 36. She doesn’t smoke and neither do ...

Senescent fibroblasts are aging cells that no longer divide and protect against tumor development. Yet two decades have gone ...

DELFI Diagnostics, Inc., developer of accessible blood-based, liquid biopsy tests that deliver a new way to enhance early cancer detection, announced that researchers from NYU Langone Health, in ...

Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new ...

The FDA granted traditional approval to pirtobrutinib (Jaypirca) for relapsed/refractory chronic lymphocytic leukemia/small ...

Squamous cell carcinoma treatment varies by stage, involving surgery, radiation, and systemic therapies based on cancer ...

Dr. Girindra Raval sat down for an interview with CURE to discuss what patients with EGFR-mutated lung cancer should know about their treatment options, highlighting the latest advancements in ...

Elevar plans resubmission of a New Drug Application to the U.S. Food and Drug Administration for the combination therapy of camrelizumab and rivoceranib in January 2026.

The companies plan to test the treatment's efficacy in preclinical models of squamous cell lung carcinoma early next year.

Senescent fibroblasts are aging cells that no longer divide and protect against tumor development. Yet two decades have gone ...